Crossmark

The prevalence of cancer in patients with multiple sclerosis (MS) who received rituximab: a systematic review and meta-analysis

Crossref DOI link: https://doi.org/10.1016/j.nrleng.2022.07.004

Published Print: 2025-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Mirmosayyeb, O.

Shaygannejad, V.

Ebrahimi, N.

Ghoshouni, H.

Ghajarzadeh, M.
License Information

Text and Data Mining valid from 2025-01-01

Text and Data Mining valid from 2025-01-01

Version of Record valid from 2022-08-29
More Information

This article is maintained by: Elsevier

Article Title: The prevalence of cancer in patients with multiple sclerosis (MS) who received rituximab: a systematic review and meta-analysis

Journal Title: Neurología (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.nrleng.2022.07.004

Content Type: article

Copyright: © 2022 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Neurología.